ET Wealth collaborates with Value Research to analyse top mutual funds. We examine the key fundamentals of the fund, its portfolio and performance to help you make an informed investment decision.

BASIC FACTS

DATE OF LAUNCH

28 DECEMBER 2015

CATEGORY

EQUITY

TYPE

ELSS

AUM*

Rs.12,615 crore

BENCHMARK

NIFTY 500 TOTAL

RETURN INDEX

WHAT IT COSTS
NAV**

GROWTH OPTION

Rs.31.04

IDCW

Rs.21.1

MINIMUM INVESTMENT

Rs.500

MINIMUM SIP AMOUNT

Rs.500
EXPENSE RATIO*** (%)

1.72

EXIT LOAD

0%

*AS ON 31 JULY 2022
**AS ON 6 SEPTEMBER 2022
***AS ON 31 JULY 2022

FUND MANAGER

NEELESH SURANA

TENURE: 6 YEARS, 9 MONTHS

Recent portfolio changes
New Entrants:

Delhivery. NUVOCO Vistas Corp, PB Fintech.

Complete Exits: Ashok Leyland, Cholamandalam Investment & Finance, Dr. Reddy’s Labs, FSN E-Commerce Ventures, Power Finance Corp, Voltas, Ambuja Cements.

Increasing allocation: Aurobindo Pharma, Axis Bank, Bharti Airtel, Emami, Gland Pharma, Greenply Inds, Havells India, Indian Energy Exchange, Krishna Institute of Medical Sciences, National Aluminium Company.

Should you buy?

This fund retains the overarching principles of its larger siblings— Mirae Asset Large Cap and Mirae Asset Emerging Bluechip—with emphasis on quality of earnings, without overpaying for it. While it lies at the intersection of the two offerings in terms of market cap positioning, the fund borrows ideas more from Emerging Bluechip, managed by the same fund manager. However, it tends to give higher weight to large caps compared to mid cap ideas from the same fund. The fund portfolio has expanded but retains large positions in its top bets. It has replicated the fund house’s impressive track record of outperformance within a short span of time, but has seen a dip over the last year. Investors can take comfort in the proven capabilities of its fund manager to steer the fund in the right direction.